These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 23747777)

  • 1. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
    Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
    J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban (Xarelto) for acute coronary syndrome.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
    Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
    J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
    Mega JL; Braunwald E; Wiviott SD; Murphy SA; Plotnikov A; Gotcheva N; Ruda M; Gibson CM
    Am J Cardiol; 2013 Aug; 112(4):472-8. PubMed ID: 23711804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
    Mega JL; Braunwald E; Mohanavelu S; Burton P; Poulter R; Misselwitz F; Hricak V; Barnathan ES; Bordes P; Witkowski A; Markov V; Oppenheimer L; Gibson CM;
    Lancet; 2009 Jul; 374(9683):29-38. PubMed ID: 19539361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for the treatment of acute coronary syndromes.
    Wong CK; White HD
    Expert Opin Pharmacother; 2013 May; 14(7):917-27. PubMed ID: 23544968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
    Gopalakrishnan L; Kumar V; Kohli P; Singh P; Rastogi U; Gibson CM
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):889-900. PubMed ID: 22577900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Ahrens I; Bode C
    Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban in the contemporary treatment of acute coronary syndromes.
    Alexander D; Jeremias A
    Expert Opin Investig Drugs; 2011 Jun; 20(6):849-57. PubMed ID: 21554163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel direct-acting anticoagulants for risk reduction in ACS.
    Dobesh PP; Oestreich JH
    J Pharm Pract; 2013 Aug; 26(4):358-66. PubMed ID: 23172897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The ATLAS ACS 2-TIMI 51 study].
    Casella G; Pavesi PC; Magnani G; Ardissino D
    G Ital Cardiol (Rome); 2012 Oct; 13(10):625-30. PubMed ID: 23022965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.